Is BSX (Boston Scientific Corp.) halal?

Q: Is BSX (Boston Scientific Corp.) halal?

HALAL: Medical-device core is generally permissible and current asset-based financial ratios pass, with product-material and mixed-income details incomplete. Boston Scientific's March 31, 2026 filing reports debt/assets of 24.87%, cash/assets of 3.28% and receivables plus cash/assets of 10.10%; gross interest income is not separately disclosed. Its cardiovascular, electrophysiology, endoscopy, urology and neuromodulation devices generally serve preservation of life, while biological materials, clinical use, access and acquisition exposure require qualitative review.

← Back to Halal Checker

BSX

Boston Scientific Corp.

HALAL — FINANCIAL SCREENS PASSstock

Is BSX Halal?

Medical-device core is generally permissible and current asset-based financial ratios pass, with product-material and mixed-income details incomplete.

What You Should Know

Boston Scientific's March 31, 2026 filing reports debt/assets of 24.87%, cash/assets of 3.28% and receivables plus cash/assets of 10.10%; gross interest income is not separately disclosed. Its cardiovascular, electrophysiology, endoscopy, urology and neuromodulation devices generally serve preservation of life, while biological materials, clinical use, access and acquisition exposure require qualitative review.

⚠️ Concerns

•Some devices may use animal-derived or biological materials requiring product-specific necessity review
•Debt is 24.87% of total assets after acquisition financing
•Gross interest income is unavailable in the examined filing
•Penumbra and other acquisition activity can change leverage and business mix
•Medical-device safety, pricing, reimbursement and regulatory access require continuing review

Current quantitative Sharia screen

Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-13.

USD · millions

Interest-bearing debt / assets

24.87%Within limit

Below 33.333% under FTSE Yasaar

11,029 / 44,351

Cash + interest-bearing securities / assets

3.28%Within limit

Below 33.333% under FTSE Yasaar

1,453 / 44,351

Receivables + cash / assets

10.10%Within limit

Below 50% under FTSE Yasaar

4,480 / 44,351

Methodology	Financial	Overall	What drives it
FTSE Yasaar v4.6, February 2026	Incomplete	Incomplete	Debt is 24.87%, liquidity is 3.28% and receivables plus cash are 10.10%; the examined asset ratios pass, but the FTSE income comparison is incomplete because gross interest income is unavailable.
MSCI Islamic (total-assets series) October 2024 methodology	Pass	Incomplete	Debt is 24.87%, liquidity is 3.28% and receivables plus cash are 10.10%, below the examined MSCI total-assets limits. This is a calculation against the named method, not an index-membership claim.
Malaysia SAC financial ratios single 5% activity benchmark adopted November 2025	Pass	Incomplete	Debt is 24.87% and liquidity is 3.28%, below the examined Malaysia SAC financial limits. This is a calculation against SAC ratios, not an official classification of a U.S.-listed security.
Market-cap denominator methods MSCI M-Series, S&P and Dow Jones methods differ	Not calculated	Not calculated	A properly licensed and reproducible historical market-cap series is not stored, so these methods are not estimated from a current spot price.

FTSE Yasaar

v4.6, February 2026

Financial: Incomplete
Overall: Incomplete

Debt is 24.87%, liquidity is 3.28% and receivables plus cash are 10.10%; the examined asset ratios pass, but the FTSE income comparison is incomplete because gross interest income is unavailable.

MSCI Islamic (total-assets series)

October 2024 methodology

Financial: Pass
Overall: Incomplete

Debt is 24.87%, liquidity is 3.28% and receivables plus cash are 10.10%, below the examined MSCI total-assets limits. This is a calculation against the named method, not an index-membership claim.

Malaysia SAC financial ratios

single 5% activity benchmark adopted November 2025

Financial: Pass
Overall: Incomplete

Debt is 24.87% and liquidity is 3.28%, below the examined Malaysia SAC financial limits. This is a calculation against SAC ratios, not an official classification of a U.S.-listed security.

Market-cap denominator methods

MSCI M-Series, S&P and Dow Jones methods differ

Financial: Not calculated
Overall: Not calculated

A properly licensed and reproducible historical market-cap series is not stored, so these methods are not estimated from a current spot price.

Business-activity disclosure

Boston Scientific develops and manufactures medical devices for cardiovascular, electrophysiology, endoscopy, urology, neuromodulation and related procedures. Medical devices that treat disease and preserve life are generally permissible, while product-specific materials, clinical use, pricing and acquisition exposures require continuing review.

Limitation: The filing does not allocate revenue by product material, procedure, end use, customer contract or downstream clinical application into a universal prohibited-revenue numerator; no blanket zero-concern claim is made.

Purification

Boston Scientific does not separately disclose gross interest income in the examined filing and does not prescribe a scholar-approved purification percentage. Readers should follow the qualified scholar or methodology they use rather than applying the old unsupported 0.5% estimate.

Inputs, assumptions and primary sources

Inputs use Boston Scientific's March 31, 2026 Form 10-Q; amounts are USD millions as presented in the filing.
Debt uses $41 million of current debt obligations plus $10,988 million of long-term debt. Finance leases are not entered as conventional debt.
Cash uses $1,453 million of cash and cash equivalents. The filing identifies money-market funds and time deposits within cash and other current assets; no separately reported fixed-income securities balance is added to avoid double counting.
Receivables use $3,027 million of trade accounts receivable, net. Factored receivables derecognized from the balance sheet are not added.
Quarterly net sales are $5,203 million. The filing reports other, net of $151 million but does not separately disclose gross interest income, so no income percentage is estimated.

U.S. Securities and Exchange Commission: Boston Scientific Q1 2026 Form 10-Q FTSE Russell: FTSE Yasaar Global Equity Shariah Index Series Ground Rules MSCI: MSCI Islamic Index Series Methodology Securities Commission Malaysia: Shariah-Compliant Securities Screening Methodology

This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.

🧾

Own BSX? Purify your portfolio.

Per-holding purification amounts, zakat on your shares, and halal alternatives for flagged holdings — a personalized report prepared for you within 48 hours.

Order Your Report — $49 →

Track BSX and 30,000+ stocks' live compliance status with Islamicly — 50% off with code ZAKAT50.Get Islamicly →